1. Cytogenotoxicity assessment of polyoxopalladates(II) as promising antileukemic drug candidates
- Author
-
Čolović, Mirjana, Gajski, Goran, Gerić, M., Ma, T., Ma, X., Kortz, Ulrich, Krstić, Danijela, Čolović, Mirjana, Gajski, Goran, Gerić, M., Ma, T., Ma, X., Kortz, Ulrich, and Krstić, Danijela
- Abstract
Polyoxopalladates(II) (POPs) are discrete, anionic palladium(II)- oxo nanoclusters that possess features of both conventional polyoxometalates (POMs) and palladium(II), which were shown to exhibit promising antitumor properties. In this study, in vitro cyto- and genotoxicity evaluation was performed on normal non-target human blood cells using two isostructural POPs with tetravalent metal ions (SnIV, PbIV) encapsulated in the cuboid Pd12-oxo host, Na12[SnO8Pd12(PO4)8]·43H2O (SnPd12) and Na12[PbO8Pd12(PO4)8]·38H2O (PbPd12), with confirmed in vitro antileukemic actions against HL-60 cell line. For this purpose, whole blood samples were exposed to the POPs, at concentrations of ≈ IC50 (24 h) values, resulting in cytotoxicity in HL-60 cells for 24 h at 37 °C. The cytotoxicity studies were performed on human peripheral blood mononuclear cells which were stained with acridine orange and ethidium bromide, and then viewed under a fluorescence microscope. The genotoxicity was tested in whole blood by the alkaline comet assay (microgel electrophoresis). The results of the cytotoxicity evaluation and the comet assay demonstrated that none of the tested POPs, within the investigated concentration range 12.5 – 50 µM, resulted in a statistically significant modulation of blood cell viability as well as DNA damage, expressed as % of tail DNA (relative increase of tail DNA), compared to the untreated controls. Therefore, the promising antileukemic drug candidates, SnPd12 and PbPd12, can be considered as selective and safe from a cytogenotoxicity point of view.
- Published
- 2021